Myriad is a biopharmaceutical company focused on the development of novel
healthcare products. In addition to an expanding preclinical pipeline,
our drug discovery and development is strong in the areas of cancer and antivirals. We also develop and market predictive and
personalized medicine products such as:
A genetic test for hereditary breast and ovarian cancer
A genetic test for hereditary melanoma
A genetic test for adenomatous polyposis syndromes
A genetic test for hereditary nonpolyposis colorectal cancer (HNPCC)
A genetic test to predict toxicity to 5-FU/capecitabine-based chemotherapy
